Filing Analysis
Precision BioSciences, Inc. entered into a First Amendment to its Amended and Restated Loan and Security Agreement with Banc of California on June 10, 2026. The primary purpose of the amendment was to extend the maturity date of the company's Term Loan.
📋 Key Facts
- Agreement date: June 10, 2026
- Lender: Banc of California
- The maturity date of the Term Loan was extended from June 30, 2027, to December 31, 2029
- The amendment modifies a previous agreement dated July 31, 2024
Precision BioSciences announced new biopsy and clinical data from the Phase 1 ELIMINATE-B trial for chronic hepatitis B (PBGENE-HBV). The data shows a 10-fold reduction in cccDNA-derived transcripts and 100% pgRNA loss in patients with detectable pgRNA at baseline.
🚩 Red Flags
- One patient experienced two serious adverse events (SAEs) in the highest dose cohort, although the company claims these are now mitigated.
📋 Key Facts
- PBGENE-HBV demonstrated a 1-log (10-fold) reduction in cccDNA-derived transcripts.
- pgRNA loss was achieved in 100% of patients (n=6) with detectable pgRNA at baseline.
- 38 doses administered across 16 patients in 5 cohorts for safety analysis.
- No dose limiting toxicities observed.
- One patient in the highest dose cohort (0.8 mg/kg) experienced two serious adverse events (SAEs) related to hypotension.
- Mitigation protocols (slower infusion rate, increased steroids) have been implemented to address hypotension and LNP-related ALT/AST abnormalities.
Precision BioSciences, Inc. reported the results of its annual meeting of stockholders held on May 21, 2026. Stockholders approved an amendment to the 2019 Incentive Award Plan to increase the share pool by 3,800,000 shares and approved an amendment to the Certificate of Incorporation to allow for officer exculpation.
🚩 Red Flags
- Significant stockholder opposition to Proposal 4 (Incentive Award Plan amendment) with 8,145,992 votes against versus 11,170,635 votes for, indicating potential investor concern over dilution.
📋 Key Facts
- Stockholders approved an amendment to the 2019 Incentive Award Plan, increasing the shares of Common Stock available for issuance by 3,800,000 shares.
- An amendment to the Certificate of Incorporation was approved and filed on May 22, 2026, to provide for the exculpation of certain officers as permitted by Delaware law.
- Melinda Brown and Geno Germano were elected as Class I directors to serve until 2029.
- Deloitte & Touche LLP was ratified as the independent registered public accounting firm for the fiscal year ending December 31, 2026.
Precision BioSciences announced its financial results for the first quarter ended March 31, 2026. The results were disclosed via a press release furnished as an exhibit to the filing.
📋 Key Facts
- The filing reports financial results for the fiscal quarter ended March 31, 2026.
- The report was filed on May 5, 2026, under Item 2.02 (Results of Operations and Financial Condition).
- The information is furnished and not deemed 'filed' for purposes of Section 18 of the Exchange Act.
- The filing was signed by John Alexander Kelly, Chief Financial Officer.
Precision BioSciences hosted a Key Opinion Leader (KOL) event on March 17, 2026, to discuss the Duchenne muscular dystrophy (DMD) treatment landscape and the company's clinical progress. The event focused on the PBGENE-DMD program and the FUNCTION-DMD Phase 1/2 clinical trial.
📋 Key Facts
- The event featured Dr. Aravindhan Veerapandiyan, a pediatric neurologist, and Pat Furlong, Founding President of Parent Project Muscular Dystrophy.
- The presentation provided an overview of the PBGENE-DMD program and the FUNCTION-DMD Phase 1/2 clinical trial.
- The company furnished the presentation materials as Exhibit 99.1.
- The event was held via live webcast on March 17, 2026, at 9:00 a.m. ET.
Precision BioSciences, Inc. announced its financial results for the fourth quarter and fiscal year ended December 31, 2025. The results were disclosed via a press release furnished as Exhibit 99.1 to the filing.
📋 Key Facts
- Filing date: March 12, 2026
- Reporting period: Quarter and fiscal year ended December 31, 2025
- The company furnished the information under Item 2.02 (Results of Operations and Financial Condition)
- John Alexander Kelly, Chief Financial Officer, signed the report